Dr. Minoo Battiwalla

Dr. Minoo Battiwalla, MD, MS, is a distinguished leader in hematologic oncology, specializing in blood cancers and stem cell transplantation. He serves as Director of Blood Cancer Outcomes Research for the Sarah Cannon Transplant and Cellular Therapy Network, affiliated with TriStar Centennial Medical Center in Nashville. Dr. Battiwalla earned his medical degree from Calcutta Medical College, completed an internal medicine residency at Stony Brook University Hospital, and a fellowship in hematology/oncology and bone marrow transplantation at the National Institutes of Health. He also holds an MS in Clinical Research from Duke University School of Medicine. Prior to his current role, he served as Medical Director of the Blood and Marrow Transplant Program at the National Heart, Lung, and Blood Institute and chaired the NIH BMT Consortium.

Dr. Battiwalla is known for his expertise in designing and leading outcomes research focused on survivorship, treatment efficacy, and late effects following stem cell transplantation and cellular therapies. He has co-chaired major initiatives such as the NIH Late Effects After BMT consensus group and the Center for International Blood and Marrow Transplantation Late Effects Working Committee. His work has driven advances in optimizing post-transplant care and integrating long-term follow-up strategies into clinical practice, with numerous peer-reviewed publications detailing real-world outcomes and survivorship patterns.

Beyond his research leadership, Dr. Battiwalla is a committed educator and mentor. He guides fellows, clinical investigators, and junior faculty in retrospective outcomes science and complex study design within the transplantation and cellular therapy space. He is widely respected for his analytical approach and patient-centered research philosophy. Through his leadership in outcomes research, translational data integration, and academic mentorship, Dr. Battiwalla continues to advance survivorship care and outcome optimization in hematologic malignancies and transplant medicine.